| ||
| Synta Announces Ganetespib Phase 2 Non-small Cell Lung Cancer Trial Results ... Business Wire (press release) (NASDAQ: SNTA) today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in advanced non-small cell lung cancer (NSCLC) that showed promising clinical ... See all stories on this topic » | ||
| Talactoferrin Benefits Broad Range Of Lung Cancer Patients Medical News Today The investigational immunomodulatory agent talactoferrin boosts survival compared to placebo in multiple prognostically important subsets of patients with non-small cell lung cancer (NSCLC) who have failed first- or second-line therapy, according to ... See all stories on this topic » | ||
| Vandetanib Superior to Placebo in Progression-Free Survival in NSCLC; No ... Monthly Prescribing Reference CHICAGO—Vandetanib maintenance therapy demonstrated longer progression-free survival rates in patients with recurrent non-small cell lung cancer (NSCLC) compared to those receiving placebo as reported by Joseph Aisner, MD, of the Cancer Institute of ... See all stories on this topic » | ||
| Final Phase III Data from Study CA031 of ABRAXANE® in Combination with ... National Post (registration) ABRAXANE is currently in various stages of investigation for the treatment of the following cancers: expanded applications for metastatic breast, non-small cell lung, malignant melanoma, pancreatic and gastric. The US Food and Drug Administration ... See all stories on this topic » | ||
| Docetaxel + Cisplatin vs. Mitomycin, Vindesine + Cisplatin with Concurrent ... Monthly Prescribing Reference CHICAGO—A long-term follow up on a Phase 3 study for locally advanced non-small cell lung cancer (NSCLC) showed that docetaxel and cisplatin (DP) chemotherapy with concurrent thoracic radiation therapy (TRT) vs. mitomycin, vindesine, and cisplatin ... See all stories on this topic » | ||
| Relay participants commit to cancer fight Marion Star Her father is a lung cancer survivor and her father-in-law died of leukemia. Friends also had been affected by cancer. "It's the first step of not feeling helpless," Harris, who attends Marion Technical College, said of her decision to coordinate the ... See all stories on this topic » | ||
| Vadimezan Failed to Improve Efficacy When Combined with Carboplatin/Paclitaxel ... Monthly Prescribing Reference ... although generally well-tolerated, did not demonstrate enhanced efficacy over placebo in patients with advanced non-small cell lung cancer (NSCLC), according to data presented at the American Society of Clinical Oncology's 2011 Annual Meeting. ... See all stories on this topic » | ||
| SAFE THAN SORRY Calcutta Telegraph And finally, there is no substitute for caution. Until a few decades ago, a great many doctors pooh-poohed any correlation between smoking and lung cancer. Who knows what new ironies lie in store for the generations to come? See all stories on this topic » | ||
| Seeing the Future of Cancer-Associated Transcription Factor Drug Targets Journal of American Medical Association (subscription) Examples of such inhibitors are the nutlins, the spirooxindoles (discovered via molecular modeling), and JNJ-26854165, a tryptamine-derived MDM2 inhibitor with activity against glioblastoma and lung cancer models, which is undergoing phase 1 trial ... See all stories on this topic » | ||
| Final Phase III Data from Study CA031 of ABRAXANE® in Combination with ... Genetic Engineering News (press release) Celgene International Sàrl (Nasdaq:CELG) today announced that final results from a phase III study of ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) in combination with carboplatin in patients with advanced non-small cell lung ... See all stories on this topic » | ||
| Tarceva nearly doubled the time people with a genetically distinct type of ... pharmabiz.com Roche announced results of Eurtac, the first phase III study with Tarceva (erlotinib) in Western patients with a genetically distinct type of advanced Non-Small Cell Lung Cancer (NSCLC). Eurtac showed that first-line Tarceva nearly doubled the time ... See all stories on this topic » | ||
|
| ||
| ASCO 2011: Erbitux Increased Overall Survival by 5.1 Months in ... By MENewswire Merck is also investigating among other potential cancer treatments the use of Stimuvax® (BLP25 Liposome Vaccine) in the treatment of non-small cell lung cancer. The vaccine was granted fast-track status in September 2004 by the FDA. ... SmartOman.com - Press Release - http://pressrelease.smartoman.com/ |
| ||
| Synta Announces Ganetespib Phase 2 Non-small Cell Lung Cancer ... Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 ... www.freshnews.com/.../synta-announces-ganetespib-phase-2-n... | ||
| Progress Against Lung Cancer 2000: Study links household radon exposure to lung cancer. 2000: Second round of chemotherapy boosts survival in advanced non-small cell lung cancer ... www.cancerprogress.net/.../progress_against_lung_cancer_slid... | ||
| Small Cell Lung Cancer Video Small Cell Lung Cancer Video - Jim Gibson. Complete remission of lung tumor through Issels Treatment in March 2003. Update: MRIs and CT scans of 2005, ... video.ezinemark.com/small-cell-lung-cancer-44392837ee0.html |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment